303 papers found
Refreshing results…
444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration
Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
Global dynamics of healthy and cancer cells competing in the hematopoietic system
Increased oxidative stress with substantial dysregulation of genes related to oxidative stress and DNA repair after laparoscopic colon cancer surgery
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?
Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
Age‐related prevalence and clinical significance of neutropenia ‐ isolated or combined with other cytopenias: Real world data from 373 820 primary care individuals
Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Smoking, blood cells and myeloproliferative neoplasms: meta‐analysis and Mendelian randomization of 2·3 million people
The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera
Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Missing publications? Read more about our data sources.